Individualized neoantigen peptide cancer vaccines can require more than 20 patient-specific peptides per patient, made at small scale on an expedited timeline, yet international purity-testing standards are still missing. The FRAME-001 case, 24 peptides synthesized in 19 days and a complete…
Individualized neoantigen peptide cancer vaccines can require manufacturing more than 20 patient-specific peptides for a single patient, at small scale and on an accelerated timeline, while international purity-testing standards for those products remain absent. GenScript, a contract development and manufacturing organization active in peptide production, has laid out the challenge using the FRAME-001 vaccine as a case example: 24 patient-specific neoantigen peptides synthesized within 19 days, and a complete manufacturing process finished in 48 days, for a patient with advanced non-small cell lung cancer.
The FRAME-001 workflow was originally reported by Oosting et al. 2022 , and it now stands as a reference point for what individualized vaccine manufacture actually demands. Every patient's vaccine is a unique set of peptides selected from that patient's own tumor mutations. Each set is chemistry that has never been made before at that exact composition, and each is needed quickly, because the patient's disease sets the deadline.
The regulatory framework has not caught up with the manufacturing capability. The U.S. Food and Drug Administration FDA and the European Medicines Agency EMA are still in the process of formulating guidelines for evaluating these novel drugs, and no well-established international standard exists for purity testing of individualized neoantigen peptides. Manufacturers are expected to deliver consistently pure, well-characterized products under good manufacturing practice, while the methods for proving that purity remain a matter of each laboratory's choosing.
Oosting et al. described the production of FRAME-001, a personalized neoantigen peptide vaccine intended for a patient with advanced non-small cell lung cancer. The process required synthesis of 24 patient-specific neoantigen peptides. Synthesis was completed within 19 days. The complete manufacturing process, from synthesis through the finished vaccine product, took 48 days.
Those numbers set the performance bar for the category. Personalized neoantigen peptide vaccines conventionally require manufacturing more than 20 different peptides per patient, on a smaller scale and under an expedited timeline, and FRAME-001 sits at the demanding end of that range. Twenty-four peptides in 19 days means the production line released, on average, more than one patient-specific peptide per day, with each peptide passing through synthesis, purification, analytical testing, and release before the vaccine could be formulated.
The scale is small by pharmaceutical standards. A single patient's 24 peptides amount to a batch size far below most commercial peptide products. But the diversity is the complication. Each peptide in the set has its own sequence, its own solubility, its own stability, and its own behavior in every analytical method applied to it. A workflow tuned for one patient's peptides must be retuned for the next patient's, because the next 24 sequences are all different. The 48-day total, which includes analytical testing and release, defines how quickly a patient with advanced non-small cell lung cancer could begin vaccination.
Neoantigens are the reason these vaccines exist, and their origins explain why so many peptides are needed per patient. Xie et al. 2023 described the formation mechanisms. Neoantigens can arise from genomic events such as single-nucleotide variations, insertions and deletions, and gene fusions; from transcriptional events such as alternative splicing of pre-mRNA; and from dysregulated translational and post-translational events. In all of these cases the result is a peptide sequence that the immune system has not encountered before, because it is not present in the normal human proteome.
The intended mechanism of action is simple in outline. Neoantigen peptides are designed to activate the patient's immune system against tumor-specific antigens. If the vaccine works, the resulting T-cell response may kill cancer cells and potentially control or eliminate the tumor. Those verbs are deliberately conditional, because the evidence discussed in the final section does not yet demonstrate clinical effect.
Not all neoantigens pose the same manufacturing problem. Public neoantigens come from driver mutations in key genomic areas or hot spots, and they can be used in vaccines for many patients, because many patients' tumors carry the same mutation. Private neoantigens are patient-specific, unique to one person's tumor, and they require highly personalized manufacturing. The practical consequence is direct: a public-neoantigen vaccine can be made once and given to many patients, while a private-neoantigen vaccine is effectively a one-off product, designed, synthesized, tested, and released after a single patient's tumor has been analyzed.
The FDA and EMA sit at the center of this question. Both agencies regulate clinical studies and approval of neoantigen cancer vaccines. Both require manufacturing suppliers of individualized neoantigen peptides to comply with good manufacturing practice standards and to implement quality control measures. That obligation binds every facility in the chain, from the supplier of the synthesized peptides to the organization that formulates and releases the final vaccine. Drug regulatory agencies generally face the same ambiguity, because no harmonized international standard exists.
What neither agency has yet done is settle how purity should be measured for these products. Regulators are still in the process of formulating guidelines for the evaluation of neoantigen peptide drugs. The unclear purity-testing requirements complicate test-method development, because a method developed today may not match the specification that a future guideline establishes.
The regulatory concern extends beyond chemistry to immunology. Agencies weigh the potential for autoimmune reactions and cross-reactivity with self-antigens in healthy tissues, because a vaccine directed at tumor-specific peptides could, in principle, prime T cells that also recognize related sequences on normal cells. Immune-related adverse events, including inflammation of organs such as the lungs, liver, and intestines, are a concern with neoantigen peptides. These are risks to be managed in clinical trials rather than observed outcomes reported from FRAME-001, for which no safety data appear in the manufacturing analysis.
Purity testing of neoantigen peptides is difficult for reasons intrinsic to the molecules. The first is high sequence diversity: a single patient's set contains more than 20 distinct peptides with no shared reference sequence. The second is that each peptide has unique physicochemical properties; solubility, charge, hydrophobicity, and chemical behavior differ from sequence to sequence. The third is peptide instability, with each sequence degrading at its own rate.
The consequence is that a purity method validated for one peptide is not automatically valid for the next. Laboratories may use different methods, and even the same laboratory may switch methods between products, leading to inconsistent results. There are no well-established international standards for purity testing of individualized neoantigen peptide drugs, no shared reference materials, and no consensus on how purity should be expressed for a product that is never made twice.
Manufacturers nonetheless face fixed obligations under GMP. They must produce consistent peptide products where consistency is possible, maintain high purity, minimize truncated peptides and side-reaction products from the synthesis chemistry, ensure supply-chain traceability, and balance customization with standardized quality control. Each of those obligations is harder to satisfy when the acceptance criteria are not defined by any harmonized standard, and when the impurities that matter most, such as truncated sequences with properties closely similar to the full-length product, are the hardest to measure.
For peptide manufacturers, analytical method development is now the critical path. A process for 24 peptides is only as fast as its release testing. The FRAME-001 timeline, with all 24 peptides synthesized within 19 days and the complete process finished in 48 days, implies that purification and analysis ran in parallel with synthesis. Any rework, any failed release assay, any out-of-specification result would have pushed the total past 48 days.
For researchers, the FRAME-001 workflow is both a benchmark and a caution. It shows that bespoke multi-peptide vaccines can be made on a clinical timeline. It also shows that study results will be difficult to compare across laboratories until purity methods are harmonized, because differences in measured purity can reflect the method rather than the product. A peptide reported as highly pure by one laboratory's assay might read differently under another's.
For the supply chain, the lesson is traceability. GMP requires documented control of starting materials, intermediates, and finished peptides, and the individualized nature of the product removes the usual protection of repeat batches, where problems surface after several production runs. For clinicians, the direct implication is the timeline: the 19-day synthesis window and the 48-day total process define the earliest moment at which a patient's personalized vaccine can be ready, and the lack of agreed purity standards means the quality evidence supporting that vaccine may vary from one manufacturing site to the next.
This analysis establishes production capability, not clinical effect. No efficacy, safety, or patient outcome data are reported for FRAME-001, and sample sizes are not given. Tumor control or elimination is described only as a potential outcome, not a demonstrated benefit. Autoimmunity and immune-related adverse events are concerns, not observed outcomes. The FRAME-001 workflow data are cited from Oosting et al. 2022 , and the neoantigen mechanisms from Xie et al. 2023 ; the analysis reproduced Figure 1 from Oosting et al. without modifications and only panel a of Figure 2 from Xie et al. No independent manufacturing or clinical data are provided.
The open questions are specific. How should international purity-testing standards and reference materials for individualized neoantigen peptides be established, and which body should own them? Which testing methods can reliably quantify purity across highly diverse and unstable peptide sequences? How can manufacturers maintain standardized quality control while customizing each patient's neoantigen peptide set? What specific purity-testing guidelines will agencies such as the FDA and EMA adopt, and when? And what efficacy, safety, and outcome data exist for FRAME-001, which the manufacturing literature does not report?
The answers will determine whether individualized neoantigen vaccines become a reproducible therapeutic platform or remain a high-effort exception. The FRAME-001 case shows the field can make 24 patient-specific peptides in 19 days and finish a vaccine in 48. The missing purity standard shows the field cannot yet prove, in a way that regulators and other laboratories accept, exactly what it made.
Vendors referenced: Genscript.
Related reading: Manufacturing bottlenecks stall personalized neoantigen peptide vaccines, Porton Advanced Secures China Class C Drug Manufacturing License, Donald Bachem Obituary Notice: Wilmington, North Carolina, Piramal Pharma adds spray drying suite at Turbhe peptide site.